{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:48:36Z","timestamp":1791643716510,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.tmrv.2022.06.008","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T11:33:43Z","timestamp":1661600023000},"page":"230-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-9783","authenticated-orcid":false,"given":"Itay","family":"Lotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9451","key":"10.1016\/j.tmrv.2022.06.008_bib0001","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.tmrv.2022.06.008_bib0002","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.tmrv.2022.06.008_bib0003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.tmrv.2022.06.008_bib0004","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.tmrv.2022.06.008_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.tmrv.2022.06.008_bib0006","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tmrv.2022.06.008_bib0007","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10206","key":"10.1016\/j.tmrv.2022.06.008_bib0008","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tmrv.2022.06.008_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728214.2022.2059463","article-title":"Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients","volume":"27","author":"Carnero Contentti","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/j.tmrv.2022.06.008_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.tmrv.2022.06.008_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cen3.12394","article-title":"Neuromyelitis optica spectrum disorders: emerging therapies","volume":"8","author":"Araki","year":"2017","journal-title":"Clin Exp Neuroimmunol"},{"issue":"3","key":"10.1016\/j.tmrv.2022.06.008_bib0012","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","article-title":"Sera from neuromyelitis optica patients disrupt the blood-brain barrier","volume":"83","author":"Shimizu","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.tmrv.2022.06.008_bib0013","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1172\/JCI60842","article-title":"Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease","volume":"122","author":"Argaw","year":"2012","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.tmrv.2022.06.008_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0b013e318204a3af","article-title":"The paradoxical effect of bevacizumab in the therapy of malignant gliomas","volume":"76","author":"Thompson","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.tmrv.2022.06.008_bib0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen3.12239","article-title":"Bevacizumab is safe in acute relapses of neuromyelitis optica","volume":"6","author":"Mealy","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"issue":"3","key":"10.1016\/j.tmrv.2022.06.008_bib0016","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.tmrv.2022.06.008_bib0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell-B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.tmrv.2022.06.008_bib0018","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.tmrv.2022.06.008_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"issue":"25","key":"10.1016\/j.tmrv.2022.06.008_bib0020","doi-asserted-by":"crossref","first-page":"e15944","DOI":"10.1097\/MD.0000000000015944","article-title":"A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder","volume":"98","author":"Mealy","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tmrv.2022.06.008_bib0021","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.tmrv.2022.06.008_bib0022","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1212\/NXI.0000000000000005","article-title":"Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica","volume":"1","author":"Levy","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.tmrv.2022.06.008_bib0023","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.tmrv.2022.06.008_bib0024","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1352458512440060","article-title":"Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein","volume":"18","author":"Herges","year":"2012","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.tmrv.2022.06.008_bib0025","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1515\/hsz-2014-0161","article-title":"Immune-modulating effects of alpha-1 antitrypsin","volume":"395","author":"Ehlers","year":"2014","journal-title":"Biol Chem"},{"issue":"9","key":"10.1016\/j.tmrv.2022.06.008_bib0026","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.tmrv.2022.06.008_bib0027","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1016\/j.tmrv.2022.06.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.tmrv.2022.06.008_bib0029","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.06.008_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.tmrv.2022.06.008_bib0031","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:05Z","timestamp":1760138405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796322000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0887796322000372"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.06.008","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}